Abstract:75 Objectives Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are all known to affect dopaminergic neurons and often present with similar clinical features. Dopamine transporter (DAT) imaging can demonstrate presynaptic dopaminergic neuronal loss in PD, MSA and PSP. However, differentiating atypical parkinsonism from PD is often difficult. In this study, we investigated differences in striatal subregional DAT loss in PD, MSA and PSP, as well as the diagnostic value of 11C-CFT PET imaging in the differential diagnosis of parkinsonism. Methods Brain 11C-CFT PET imaging was performed in 219 patients with parkinsonian disorders. The PET images were spatially normalized and a standardized set of regions of interest (ROIs) were defined bilaterally for the caudate, anterior putamen (AP), posterior putamen(PP), ventral putamen (VP), dorsal putamen (DP) and occipital cortex with ScAnVP software. The nondisplaceable binding potential (BPND; defined as the ratio of (striatum-occipital)/occipital radioactivity counts) of each striatal subregion and intersubregional ratio (ISR; defined as the ratio of the BPND of one subregion to that of another subregion) were calculated. After the imaging, these patients were assessed by blinded movement disorders specialists for a mean of 2.3 years before a final clinical diagnosis was made. The accuracy of DAT imaging-based classification was assessed by comparison with the final clinical diagnosis. Results 133 patients had a final clinical diagnosis of PD, 55 MSA, and 31 PSP with severity matched. The BPND of caudate in the PSP group was significantly lower than those in the PD and MSA groups. The ISR of each subregional putamen/caudate in the PSP group was significantly higher than those in the PD and MSA groups. At the cutoff value of 1.16, the AP/C ISR had 87%sensitivity and 93% specificity for differentiating PSP from PD. The classifications were also accurate for PP/C (0.63; 80% sensitivity, 88% specificity), VP/C (1.13; 87% sensitivity, 92% specificity) and DP/C (0.87; 87% sensitivity, 90% specificity) ISRs. At the cutoff value of 1.23, the AP/C ISR had 81% sensitivity and 87% specificity for differentiating PSP from MSA. The classifications were also accurate for PP/C (0.78; 68% sensitivity, 84% specificity), VP/C (1.15; 84% sensitivity, 86% specificity) and DP/C (0.98; 81% sensitivity, 82% specificity) ISRs. The BPND of DP and the ISRs of DP/non-DP subregions in the MSA group were significantly higher than those in the PD group. At the cutoff value of 0.81, the DP/AP ISR had 76% sensitivity and 82% specificity for differentiating MSA from PD. The classifications were also accurate for DP/C (0.76; 71% sensitivity, 75% specificity) and DP/VP (0.87; 76% sensitivity, 76% specificity) ISRs. Conclusions PD, MSA and PSP have different preferential subregional decreases in striatal DAT binding when examined by 11C-CFT PET imaging. The ISRs could provide valuable information to distinguish parkinsonian disorders, even in earlier stages of disease.

Comparison of the ability of different quantitative indices in 123I-FP-CIT single-photon emission computed tomography to differentiate dopaminergic neurodegenerative disease

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders

Investigating the Role of 99Mtc-Trodat-1 SPECT Imaging in Idiopathic Parkinson's Disease.

Comparable Investigation in Dopamine Transporters with 99Mtc-Trodat-1 and 131I-FP-CIT SPECT in Parkinson's Disease Patients

Subregional Patterns of Preferential Striatal DAT Loss Differ in PD, MSA and PSP

Study of dopamine transporter imaging in different stages of Parkinson's disease

A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis

Assessment of Sensitivity for Early Diagnosis of Parkinson’s Disease with ~(18)F-FP-CIT Dopamine Trans porter PET Imaging and ~(99)Tc~m-TRODAT-1 SPECT Imaging

Dopamine transporter imaging in the different stages of Parkinson's disease and UPDRS score

Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of 18F/123I‐FP‐CIT studies

PET Imaging of Dopamine Transporter(DAT)in the Diagnosis of Parkinson's Disease

Imaging of dopamine transporters in Parkinson disease: a meta-analysis of <SUP>18</SUP>F/<SUP>123</SUP>I-FP-CIT studies

Application of DAT SPECT for diagnosing and assessing idiopathic parkinson's disease

Impact of quantitative index derived from 123I-FP-CIT-SPECT on reconstruction with correction methods evaluated using a 3D-striatum digital brain phantom

Usefulness of texture analysis in 123I-FP-CIT for the differentiation of AD and DLB subtypes

The Study of 11C-Cft Pet Dopamine Transporter Imaging in Evaluating the Severity of Pd

Correlation of Striatum Dopamine Transporter Imaging and the Scores of Parkinsonian Clinical Scale in Patients with Parkinson's Disease

Dopamine Transporter PET Imaging in Patients with Progressive Supranuclear Palsy and Parkinson's Disease

Correlation analysis between 3D and plane DAT binding parameters of 11C-CFT PET/CT and the clinical characteristics of patients with Parkinson's disease

The Study On~(99m)tc -TRODAT-1 SPECT Imaging of Dopamine Transporter in Assessing the Degree about the Severityof Parkinson Disease

Quantitative Research of 11C-CFT and 18F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software